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There is little doubt that human African
trypanosomiasis (HAT) would stand on
the podium of a most-neglected diseases
contest, despite the dishearteningly high
number of other candidates. The disease
is present solely in sub-Saharan Africa.
The vast majority of patients are very poor
and live in remote rural areas of countries
recently or currently affected by deep so-
cial unrest, such as Angola, the Demo-
cratic Republic of Congo, the Republic of
Congo, Uganda, and Sudan. In these
countries, HAT due to Trypanosoma brucei
gambiense reached epidemic proportions
during the 1990s, following decades of de-
ficient surveillance and control activities.
Fortunately, the improved political situa-
tion in some countries and the conjugated
efforts of national disease-control pro-
grams, nongovernmental organizations,
and the World Health Organization
(WHO) allowed the trend to be reversed.
Despite some major uncertainties (e.g., the
proportion of patients who are not cov-
ered by existing control and surveillance
programs is unknown), it is now estimated
by the WHO that 50,000–70,000 cases of
T. brucei gambiense HAT occur annually
in Africa [1].
The disease is transmitted via the bite
of tsetse flies (Glossina species). T. brucei
gambiense HAT is a slowly evolving disease
(it progresses over months to years) that
leads to death in the absence of treatment.
After an initial stage during which the try-
panosomes remain confined to the hem-
olymphatic system (first-stage disease), the
parasites invade the CNS, leading to the
various neuropsychiatric disorders, such
as confusion, convulsions, speech and
walking disturbances, sleep disturbances,
and lethargy, of the second (or menin-
goencephalitic) stage.
The diagnosis of HAT is cumbersome
and follows a 3-step approach: screening,
parasitological confirmation (microscopic
examination of lymph node and blood
specimens), and staging (examination for
trypanosomes and for increased WBC
counts in the CSF). This staging step is
essential, because the means of treating
first- and second-stage disease differ
widely. The treatment of first-stage illness
relies on daily intramuscular injections of
pentamidine for 7–10 days. This treatment
is relatively safe and practical, allowing for
ambulatory treatment of patients. Pafur-
amidine maleate (DB289), given orally for
10 days, is being developed as an alter-
native to pentamidine that may facilitate
home-based treatment of patients with
first-stage disease.
The treatment of second-stage illness is
much more problematic. It has relied on
arsenical derivatives since the beginning of
the 20th century; in particular, it has relied
on melarsoprol since 1949. Melarsoprol is
given by slow intravenous administration
in 3–4 series of 3–4 injections (with the
old schedules) or through 10 consecutive
injections (with the modern schedule).
With either schedule, 3%–6% patients die
during or after treatment of an encepha-
lopathic syndrome (severe cerebral edema
or bleeding). Other adverse effects can also
be life-threatening, including liver toxicity,
severe enterocolitis, and diffuse peripheral
neuropathy. The high toxicity of melar-
soprol has been repetitively reported for
decades. This may have induced a certain
sense of tolerance or resignation among
some, but certainly not among first-line
caregivers who have to report patients’
deaths to relatives. Moreover, high failure
rates associated with melarsoprol have
been reported from several endemic foci
in Angola, the Democratic Republic of
Congo, Sudan, Central African Republic,
and Uganda [2].
Because the disease is fatal if left un-
treated, the use of melarsoprol was ac-
ceptable in the absence of safer alterna-
tives. This is no longer the case.
Eflornithine (difluoro-methyl-ornithine),
an ornithine decarboxylase inhibitor, was
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first used to treat patients with HAT due
to T. brucei gambiense 120 years ago [3].
The recommended dosage of 400 mg/kg
divided in 6-hourly intravenous infusions
for 14 days was shown to be efficient in
adults, but higher doses must be given in
children [4]. For almost 2 decades, pa-
tients with HAT had no access to eflor-
nithine because of high price or lack of
production. This unacceptable situation
fueled a strong advocacy campaign led by
Me´decins Sans Frontie`res and other or-
ganizations in the late 1990s. Aventis
Pharma (now Sanofi-Aventis) and the
WHO signed 2 consecutive 5-year agree-
ments in 2001 and 2006 that included fi-
nancial support for control and research
programs and the donation of the key an-
titrypanosomal drugs (pentamidine, me-
larsoprol, and eflornithine). Eflornithine
has therefore been available in the field
and widely used in control programs run
by nongovernmental organizations since
2001. In southern Sudan, 4222 patients
with second-stage HAT were treated with
eflornithine by Me´decins Sans Frontie`res
and Malteser during the period 2001–
2006. In these settings, the treatment was
safe (in-hospital case-fatality rate, 1.1%)
and effective (relapse rate, !10%) (un-
published data). Two studies demon-
strated the significantly lower rates of
death and severe adverse effects with eflor-
nithine, compared with melarsoprol, in
consecutive cohorts of Congolese and Su-
danese patients [5, 6]. Therefore, eflor-
nithine is the drug of choice for second-
stage T. brucei gambiense HAT. However,
it remains to be seen whether these good
results can be replicated in the more sim-
ple settings of government-run treatment
centers.
The introduction of eflornithine as
first-line treatment to replace melarsoprol
for patients with second-stage disease who
are receiving treatment in hospitals or
health centers run by national control pro-
grams is progressing slowly. This slowness
is mainly associated with factors that are
inherent to the complex mode of eflor-
nithine administration, which involves
substantial logistic constraints and indirect
costs (e.g., acquisition and transport of in-
fusion materials from the capital to the
field), and the need for sufficient and
trained human resources to assume ade-
quate round-the-clock nursing care.
Training workshops for regional nurses
have been organized by the WHO. Med-
ical kits containing all necessary drugs and
infusion materials have been prepared and
will be available at no cost for national
control programs. These initiatives should
facilitate—to some extent—wider field use
of eflornithine, but its complicated treat-
ment regimen (56 slow infusions admin-
istered over 14 days) will remain a chal-
lenge to its widespread implementation.
There is another concern with eflorni-
thine. Sooner or later, the widespread—
and, therefore, less controlled—use of
eflornithine as monotherapy is likely to
lead to parasite resistance, which would
have catastrophic consequences. It is thus
vital to protect the efficacy of this drug by
using it in combination regimens, an ap-
proach that has been successful for nu-
merous infectious diseases, such as HIV
infection, tuberculosis, and malaria. The
most promising option today is the com-
bination of eflornithine with oral nifur-
timox, a nitrofuran compound registered
for treatment of American trypanosomi-
asis. Nifurtimox has shown some degree
of effectiveness against second-stage HAT,
but its use as monotherapy should be dis-
couraged, because most studies have re-
ported high treatment failure rates [7, 8].
Nifurtimox has also been used in com-
bination with melarsoprol but published
data are very limited. The melarsoprol-
nifurtimox combination was shown to be
associated with a lower risk of relapse than
melarsoprol alone in one study [8], but
there are serious concerns about the safety
of this combination [9].
Preliminary data on eflornithine-nifur-
timox combination therapy originate
from 2 studies (an aborted 3-arm ran-
domized study and a case series) led by
Epicentre in northwestern Uganda [9, 10].
In total, 48 patients received 7 days of in-
travenous eflornithine (400 mg/kg per day
given in 4 infusions) and 10 days of oral
nifurtimox (15–20 mg/kg per day). The
treatment was well tolerated, with no re-
lapses observed during the 24-month fol-
low-up period. These promising results
led Epicentre, Me´decins Sans Frontie`res,
and the Ministry of Health of the Republic
of Congo to launch, in Nkayi, a random-
ized phase III study called the Nifurtimox-
Eflornithine Clinical Trial (NECT), which
compared eflornithine-nifurtimox ther-
apy with the standard 14-day course of
eflornithine therapy. The total dose of
eflornithine in the eflornithine-nifurtimox
arm was the same as that used in the 2
preliminary studies, but the drug was ad-
ministered in 2 infusions per day only.
This decision was justified by the poten-
tially large beneficial impact on feasibil-
ity—and, therefore, on field application—
of a simplified treatment schedule that
does not require full-time presence of
qualified nurses (14 eflornithine infusions
were given over 7 days, as opposed to 56
infusions given over 14 days).
The NECT was designed as a random-
ized, open-label, noninferiority trial with
a sample size calculated at 280 patients.
This objective was not reached in Nkayi
because of a low enrollment rate. The pub-
lication of partial data in this issue of Clin-
ical Infectious Diseases may raise some crit-
ical voices, but the researchers’ decision
must be interpreted in the light of the
atypical context of HAT and the urgent
need for data on treatment of second-stage
illness [11]. The authors are to be con-
gratulated for the excellent study design
and for the exceptionally high rate of fol-
low-up (95%), which highlights the ded-
ication of the research team in the field.
Fifty-two and 51 patients were treated with
eflornithine-nifurtimox and standard
eflornithine, respectively. Cure rates were
excellent (1 94%) in both arms. No HAT-
or treatment-related deaths occurred dur-
ing hospitalization or during follow-up in
the eflornithine-nifurtimox arm. The rate
of hematologic (in particular, severe neu-
tropenia) and neuropsychiatric adverse ef-
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fects appeared to be low in the eflorni-
thine-nifurtimox arm. As stated by the
authors, for the time being, none of these
findings should be considered as proof.
Since 2005, the NECT has become a
multiple-center trial, with a gradual ex-
tension to 5 other field sites (3 in the Dem-
ocratic Republic of Congo and 2 in
Uganda), under the coordination of the
Drugs for Neglected Diseases initiativeand
WHO–Tropical Diseases Research, with
several other partners (Epicentre, Me´de-
cins Sans Frontie`res, the Swiss Tropical In-
stitute, and the national HAT control pro-
grams of the Democratic Republic of
Congo and Uganda). The NECT is the
only ongoing clinical trial for second-stage
HAT, and thus, it provides the only per-
spective toward improved treatment in the
next 5 to 10 years. Research and devel-
opment of new HAT drugs have been re-
vived—for instance, through the efforts of
the Drugs for Neglected Diseases initiative
and the University of North Carolina con-
sortium—but no new drug candidate for
treatment of for second-stage illness has
reached clinical development. If the prom-
ising results presented by Priotto et al. [11]
are confirmed at the other study sites (the
definitive results of this multiple-center
study will not be available before mid-
2008), the eflornithine-nifurtimox com-
bination therapy should become the first-
line treatment of choice for second-stage
T. brucei gambiense HAT. In the meantime,
standard eflornithine therapy should be
more widely used. Nifurtimox, used as
part of combination treatment, should al-
ready be available for compassionate use
in patients who experience relapse who,
otherwise, have nothing other than death
to face.
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